Muralidharan Kesavan

Dr. Muralidharan Kesavan


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2021 in Schizophrenia Research
Verified
Journal Article
Closed access
RBRakshathi Basavaraju
Rakshathi Basavaraju
DIDhruva Ithal
Dhruva Ithal
MTMilind Vijay Thanki
Milind Vijay Thanki
ARArvinda Hanumanthapura Ramalingaiah
Arvinda Hanumanthapura Ramalingaiah
JTJagadisha Thirthalli
Jagadisha Thirthalli
MKMuralidharan Kesavan
Muralidharan Kesavan

18 April 2018 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
BVBiju Viswanath
Biju Viswanath
NRNaren P. Rao
Naren P. Rao
JNJanardhanan C. Narayanaswamy
Janardhanan C. Narayanaswamy
PSPalanimuthu T. Sivakumar
Palanimuthu T. Sivakumar
AKArun Kandasamy
Arun Kandasamy
SJSanjeev Jain
Sanjeev Jain
There is emerging evidence that there are shared genetic, environmental and developmental risk factors in psychiatry, that cut across traditional diagnostic boundaries. With this background, the Discovery biology of neuropsychiatric syndromes (DBNS) proposes to recruit patients from five different syndromes (schizophrenia, bipolar disorder, obsessive compulsive disorder, Alzheimer’s dementia and substance use disorders), identify those with multiple affected relatives, and invite these families to participate in this study. The families will be assessed: 1) To compare neuro-endophenotype measures between patients, first degree relatives (FDR) and healthy controls., 2) To identify cellular phenotypes which differentiate the groups., 3) To examine the longitudinal course of neuro-endophenotype measures., 4) To identify measures which correlate with outcome, and 5) To create a unified digital database and biorepository. The identification of the index participants will occur at well-established specialty clinics. The selected individuals will have a strong family history (with at least another affected FDR) of mental illness. We will also recruit healthy controls without family history of such illness. All recruited individuals (N = 4500) will undergo brief clinical assessments and a blood sample will be drawn for isolation of DNA and peripheral blood mononuclear cells (PBMCs). From among this set, a subset of 1500 individuals (300 families and 300 controls) will be assessed on several additional assessments [detailed clinical assessments, endophenotype measures (neuroimaging- structural and functional, neuropsychology, psychophysics-electroencephalography, functional near infrared spectroscopy, eye movement tracking)], with the intention of conducting repeated measurements every alternate year. PBMCs from this set will be used to generate lymphoblastoid cell lines, and a subset of these would be converted to induced pluripotent stem cell lines and also undergo whole exome sequencing. We hope to identify unique and overlapping brain endophenotypes for major psychiatric syndromes. In a proportion of subjects, we expect these neuro-endophenotypes to progress over time and to predict treatment outcome. Similarly, cellular assays could differentiate cell lines derived from such groups. The repository of biomaterials as well as digital datasets of clinical parameters, will serve as a valuable resource for the broader scientific community who wish to address research questions in the area.

1 December 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
VSVinit Kumar Singh
Vinit Kumar Singh
SKSneha Karmani
Sneha Karmani
PMPalash Kumar Malo
Palash Kumar Malo
HVH.G. Virupaksha
H.G. Virupaksha
DMDaliboina Muralidhar
Daliboina Muralidhar
MKMuralidharan Kesavan
Muralidharan Kesavan

1 January 2008 in Indian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
MKMuralidharan Kesavan
Muralidharan Kesavan
SSSujaya Kumara R Singeri
Sujaya Kumara R Singeri
RRRavi Philip Rajkumar
Ravi Philip Rajkumar
CCChannapatna R Chandrashekar
Channapatna R Chandrashekar
VBVivek Benegal
Vivek Benegal
Background: Early onset (EO) alcohol dependence (AD) has been found to represent a subtype of alcoholism with a distinct profile and prognosis compared to late onset (LO) alcohol dependence. Externalizing disorders, especially attention deficit hyperactivity disorder (ADHD) that may continue as attention deficit hyperactivity disorder, residual type (ADD, RT) in adulthood, may increase susceptibility to early-onset AD. Aims: To examine the relationship between ADHD and ADD, RT symptoms and age at onset of AD in a sample of Indian male patients. 70 male subjects with AD presenting to the De-Addiction Services of the National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, were studied. The study had a retrospective design. Materials and Methods: Patients were examined for evidence of past ADHD in childhood and current ADD, RT using structured instruments. Chi-square tests and odds ratios were used to express the relative risk of association of ADHD with early- and late-onset AD. Results: Significantly more EO alcoholics (19/30, 63.3%) had a history of ADHD in childhood compared to LO alcoholics (7/28, 25%, P < 0.05) ADD, RT was also over-represented in EO probands. Conclusions: The results of this study are consistent with previous research that shows a high incidence of ADHD in early-onset alcoholics. This may have important management implications.

1 January 2011 in Indian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
MKMuralidharan Kesavan
Muralidharan Kesavan
VPVivek H Phutane
Vivek H Phutane
JTJagadisha Thirthalli
Jagadisha Thirthalli
NKNaveen C Kumar
Naveen C Kumar
BGBn Gangadhar
Bn Gangadhar
Electroconvulsive therapy (ECT) is prescribed for schizophrenia patients for various indications, in our country. However, official guidelines in other countries have been cautious in prescribing ECT for schizophrenia. To study the indications for which patients with schizophrenia receive ECT. We studied records of schizophrenia inpatients receiving ECT in one year (2005) (n=101) retrospectively, as well as the consecutive data of patients between May 2007 and June 2008 (n=101) prospectively. The various indications for ECT in schizophrenia were studied by frequency analysis. Of the 202 schizophrenia patients who received ECT, the most common reason was 'to augment pharmacotherapy' in (n=116) cases. The target symptoms for which ECT was prescribed the most was catatonia (n=72). The mean number of ECTs (SD) received was 8.4 (2.8). Augmentation of pharmacotherapy was the most common indication of ECT in patients with schizophrenia.

14 February 2008 in The Primary Care Companion For CNS Disorders
Verified
Journal Article
Closed access
MKMuralidharan Kesavan
Muralidharan Kesavan
RRRavi Philip Rajkumar
Ravi Philip Rajkumar
UMUzma Mulla
Uzma Mulla
RNRaghavendra Bheemappa Nayak
Raghavendra Bheemappa Nayak
VBVivek Benegal
Vivek Benegal
From the Primary Care Companion for CNS Disorders: